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Background: This paper documents a retrospective pilot study of a novel approach for treating 
attention deficit hyperactivity disorder (ADHD) with amino acid precursors of serotonin and 
dopamine in conjunction with urinary monoamine assays subjected to organic cation transporter 
(OCT) functional status determination. The goal of this research was to document the findings 
and related considerations of a retrospective chart review study designed to identify issues and 
areas of concern that will define parameters for a prospective controlled study.
Methods: This study included 85 patients, aged 4–18 years, who were treated with a novel 
amino acid precursor protocol. Their clinical course during the first 8–10 weeks of treatment 
was analyzed retrospectively. The study team consisted of PhD clinical psychologists, individu-
als compiling clinical data from records, and a statistician. The patients had been treated with 
a predefined protocol for administering amino acid precursors of serotonin and dopamine, along 
with OCT assay interpretation as indicated.
Results: In total, 67% of participants achieved significant improvement with only amino acid 
precursors of serotonin and dopamine. In patients who achieved no significant relief of symptoms 
with only amino acid precursors, OCT assay interpretation was utilized. In this subgroup, 30.3% 
achieved significant relief following two or three urine assays and dosage changes as recom-
mended by the assay results. The total percentage of patients showing significant improvement 
was 77%.
Conclusion: The efficacy of this novel protocol appears superior to some ADHD prescription 
drugs, and therefore indicates a need for further studies to verify this observation. The findings 
of this study justify initiation of further prospective controlled studies in order to evaluate more 
formally the observed benefits of this novel approach in the treatment of ADHD.
Keywords: attention deficit hyperactivity disorder, 5-hydroxytryptophan, tyrosine, L-dopa, 
organic cation transporter assay interpretation
Introduction
A large meta-analysis (n = 171,756) published in 2007 involving the review of 303 
literature articles placed the worldwide pooled incidence of attention deficit hyperac-
tivity disorder (ADHD) at 5.29%. However, this review suggested that geographic 
location plays only a limited role in the reasons for the large variability of ADHD/
hyperactivity disorder prevalence estimates worldwide.1 This paper documents the 
results of a retrospective chart review relating to a novel serotonin and dopamine amino 
acid precursor treatment approach to ADHD which integrates organic cation transporter 
(OCT) assay interpretation.2–7 Our hypothesis was that this novel approach of admin-Neuropsychiatric Disease and Treatment 2011:7 submit your manuscript | www.dovepress.com
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istering amino acid precursors of serotonin and dopamine 
with OCT assay interpretation when indicated may have 
efficacy that is superior to some of the prescription drugs 
currently used in the treatment of ADHD.
The diagnosis of ADHD is dependent upon meeting the 
Diagnostic and Statistical Manual of Mental Disorders, 
Fourth Edition (DSM-IV) criteria in the areas of inattention, 
hyperactivity, and impulsivity which negatively affect per-
formance in school and work, as well as in relationships 
with others.8 It is a generally accepted premise that a primary 
factor in development of ADHD is the status of the mono-
amine system to include serotonin, dopamine, norepineph-
rine, and epinephrine. In response, the pharmaceutical 
industry has demonstrated, to the satisfaction of the US Food 
and Drug Administration (FDA), that certain drugs that 
impact the monoamine systems meet FDA efficacy standards. 
Examples of these drugs include neutral sulfate salts of dex-
troamphetamine and amphetamine,9 methylphenidate,10 
dexmethylphenidate,11 atomextine,12 and lisdexamfetamine 
dimesylate.13
Side effects and adverse reactions associated with ADHD 
prescription medications are significant, serious, and poten-
tially life-threatening. The following is a limited list of these 
events associated with the ADHD group of drugs as a whole, 
which include, but are not limited to:9–13
•	 Black box warning of increased risk of suicidal ideation
•	 Severe liver injury
•	 Sudden death in cases with pre-existing structural cardiac 
abnormalities or other serious heart problems
•	 Risk of stroke and myocardial infarction
•	 Exacerbation of symptoms of behavior disturbance and 
thought disorder in patients with a pre-existing psychotic 
disorder
•	 Induction of mixed/manic episodes
•	 Treatment by stimulants at usual doses can cause emer-
gent psychotic or manic symptoms, eg, hallucinations, 
delusional thinking, or mania in children and adolescents 
without prior history of psychotic illness or mania
•	 Amphetamines may impair the ability of the patient to 
engage in potentially hazardous activities such as operat-
ing machinery or vehicles
•	 Higher incidence of infection, photosensitivity reaction, 
constipation, tooth disorders, emotional liability, 
decreased libido, somnolence, speech disorder, palpita-
tion, twitching, dyspnea, sweating, dysmenorrhea, and 
impotence
•	 Integument disorders including, but not limited to, urti-
caria, rash, and hypersensitivity reactions, including 
angioedema and anaphylaxis; serious skin rashes, 
  including Stevens Johnson syndrome and toxic epidermal 
necrolysis
•	 Lowering of seizure threshold
•	 Increased aggression and hostility
•	 Contraindicated in patients with marked anxiety, tension, 
and agitation, because the drugs may aggravate these 
symptoms
•	 Risk of drug dependence
•	 Development of leukopenia and/or anemia.
These drugs do not increase the total number of neu-
rotransmitter molecules in the central nervous system. Their 
primary mechanism of action is thought to be reuptake 
  inhibition which sets up conditions that move neurotransmit-
ters from one place to another.4–8 However, previous writings 
suggest that the process of reuptake inhibition may deplete 
neurotransmitters throughout the body.4,14–19 The administra-
tion of amphetamine stimulants creates another potential area 
of concern relating to neurotoxicity.20–22
There has been no previous peer-reviewed literature 
published addressing the efficacy of amino acid precursors 
of serotonin and dopamine simultaneously administered in 
the treatment of ADHD. The immediate amino acid precur-
sors of serotonin and dopamine are 5-hydroxytryptophan 
(5-HTP) and L-3,4-dihydroxyphenylalanine (L-dopa), 
respectively. They freely cross the blood-brain barrier and 
are then synthesized into serotonin and dopamine without 
biochemical feedback inhibition. L-tryptophan and L-  tyrosine 
are immediate precursors of 5-HTP and L-dopa, respectively. 
L-tryptophan and L-tyrosine have the ability to be synthe-
sized into serotonin and dopamine, respectively. They are 
actively transported across the blood–brain barrier in com-
petition with other amino acids. Synthesis of serotonin and 
dopamine from L-tryptophan and L-tyrosine, respectively, 
is regulated by biochemical feedback. Under the approach 
of this pilot study, optimal results are dependent upon achiev-
ing a proper balance between the administered serotonin and 
dopamine precursors. 2–7
This study reviews the effects of a novel method of 
treatment involving the use of monoamine amino acid pre-
cursors that do what drugs are unable to do. This novel 
approach has the ability to increase the total number of 
neurotransmitter molecules in the central nervous system,3–7 
leading to efficacy observations that appear greater than 
those of prescription drugs without the potential for neu-
rotransmitter depletion, neurotoxicity issues, and severe 
potentially life-threatening drug side effects associated with 
prescription drugs.Neuropsychiatric Disease and Treatment 2011:7 submit your manuscript | www.dovepress.com
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Material and methods
The study included 85 children aged 4–18 years who had 
been diagnosed as having ADHD under the DSM-IV criteria 
by a licensed PhD clinical psychologist. The patients were 
then treated by a clinical psychologist. The medical charts 
and treatment results were reviewed retrospectively. Patients 
were evaluated twice during treatment with the ADHD Rating 
Scale (ADHD-RS).17 Other variables assessed via a question-
naire included: taking/not taking ADHD medicine; previous 
history of taking stimulant drugs; gender; age; perceived 
amount of improvement as noted by a conversation between 
the parent (or patient alone if an adult over 18 years) and the 
psychologist; and number of comorbid factors (eg, depression, 
cerebral palsy, chronic indigestion, hair pulling, seizures, 
autism, obsessive compulsive behavior).
The time period covered in the review was 18 months. 
The individual patients were treated for a period of 8–10 weeks 
with staggered starting of treatment. If no relief of symptoms 
was observed in the first 3–4 weeks of treatment, while 
administering the amino acid dosing protocol values of 
Tables 1 and 2, a urine sample was collected. Urinary sero-
tonin and dopamine assay results were then subjected to OCT 
assay interpretation in order to define the needed change in 
amino acid dosing values. The goal of treatment was 
  resolution of symptoms or achieving urinary serotonin 
and dopamine in the phase 3 therapeutic ranges, whichever 
came first.3–7 The amino acid dosing values of the protocol 
were developed by NeuroResearch Clinics Inc, Duluth, MN.3–7
The statistician performing data analysis had no exposure 
to any aspects of active patient treatment, prior hypotheses, 
treatment expectations, and anticipated results in the data 
relating to the study. The researchers performing the chart-
ing were also blind to any hypotheses being evaluated. 
A P value # 0.05 was considered statistically significant. 
JMP (SAS Institute, Cary, NC) software was used to perform 
the statistical analysis.
For the purposes of the study, participants 16 years of 
age and younger were placed on the pediatric dosing protocol 
(Table 1). Participants 17 years of age and older were placed 
on the adult dosing protocol (Table 2).
In addition to the basic amino acid dosing values, other 
daily cofactors generally required for synthesis of the 
monoamine and maximum benefit from the protocol were 
administered. These included vitamin C 1000 mg, calcium 
citrate 220 mg, vitamin B6 75 mg, folate 400 µg, L-lysine 
500 mg, L-cysteine 4500 mg for adults and 2250 mg for 
children, and selenium 400 µg for adults and 200 µg for 
children. In general, L-dopa in the form of standardized 
mucuna pruriens 40% was added when the recommendation 
of the first urinary OCT assay interpretation demonstrated 
its need, which was a frequent occurrence.4
Patients were seen weekly. The initiation of a treatment 
prescription with amino acid precursors of serotonin and 
dopamine was at the level 1 dosing values of Tables 1 and 2. 
If the symptoms persisted after one week of treatment, the 
dosing was advanced week to week to level 2, then level 3. 
Patients who did not achieve relief of symptoms on level 3 
dosing values had a urine sample collected after one week 
on that dosage; serotonin and dopamine levels were determined 
and reported in µg of monoamine per g of creatinine. Reported 
values were then subjected to OCT assay interpretation. 
Reporting of urinary monoamine levels as µg of mono-
amine per g of creatinine compensated for the specific gravity 
of the urine.3–7
OCT assay interpretation
Peer-reviewed publications from 2009 and 2010 outlined a 
novel urinary “three-phase model” of urinary serotonin and 
dopamine response to simultaneous administration of sero-
tonin and dopamine amino acid precursors in significant 
amounts. This three-phase model is the basis for OCT assay 
interpretation.2–7 A 2010 paper proposed a novel renal organic 
cation transporter model which potentially describes the 
etiology of the “three-phase response” of serotonin and 
dopamine during simultaneous administration of their amino 
acid precursors in varied daily dosing values.3
The urinary neurotransmitter testing model should with 
the OCT assay interpretation model used in this study. The 
urinary neurotransmitter testing model merely attempts to 
determine if urinary neurotransmitter levels are high or low, 
making no provision for phase determination or OCT 
Table 1 Pediatric protocol for patients aged 16 years of age and 
younger
mg 5-HTP/mg L-tyrosine
Morning 4 pm 7 pm
Level 1 75/750 75/750 –
Level 2 112.5/1125 112.5/1125 –
Level 3 112.5/1125 112.5/1125 112.5/1125
Table 2 Adult protocol for patients 17 years of age and older
mg 5-HTP/mg L-tyrosine
Morning Noon 4 pm
Level 1 150/1500 – 150/1500
Level 2 225/2250 – 225/2250
Level 3 150/1500 150/1500 225/750Neuropsychiatric Disease and Treatment 2011:7 submit your manuscript | www.dovepress.com
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  functional status interpretation. The flawed science behind 
the urinary neurotransmitter testing model was discussed in 
a 2010 paper.6
The serotonin and dopamine filtered at the glomerulus 
are metabolized by the kidneys, and significant amounts 
do not reach the final urine. Serotonin and dopamine found 
in the urine, in patients not suffering from a monoamine- 
secreting tumor, primarily represent monoamines that are 
newly synthesized in the proximal convoluted renal tubule 
cells of the kidneys and have never been in the central nervous 
system or peripheral system. The fate of the newly synthe-
sized serotonin and dopamine inside the proximal convoluted 
renal tubule cells is primarily dependent upon the interaction 
of the basolateral monoamine transporters and the apical 
monoamine transporters of these proximal tubule cells. The 
basolateral monoamine transporter transports both serotonin 
and dopamine to the renal interstitium where they ultimately 
end up in the peripheral system via the renal vein. The apical 
monoamine transporters transport the newly synthesized 
serotonin and dopamine not transported by the basolateral 
monoamine transporter to the proximal nephrons and, from 
there, ultimately end up in the final urine as waste.3,24
Serotonin and dopamine are found in two states. The 
endogenous state is found when no amino acid precursors 
are administered. The competitive inhibition state is found 
when significant amounts of both serotonin and dopamine 
precursors are simultaneously administered. Proper OCT 
assay interpretation requires that the serotonin and dopamine 
systems be simultaneously placed in the competitive inhibi-
tion state prior to OCT assay interpretation.3–7,24
The basis for OCT assay interpretation requires that two 
or more urinary serotonin and dopamine assays be performed 
while taking serotonin and dopamine amino acid precursors 
at significantly varied dosing values. The results are then 
compared to determine the change in urinary serotonin and 
dopamine levels in response to the change in amino acid 
precursor dosing values.2–7
A urinary serotonin or dopamine value less than 80 µg 
or 475 µg of monoamine per g of creatinine, respectively, 
is defined as a phase 2 response. A urinary serotonin or 
dopamine value greater than 80 µg or 475 µg of monoamine 
per g of creatinine, respectively, is interpreted as being in 
phase 1 or phase 3. Differentiation of phase 1 from phase 3 
is a follows. If a direct relationship is found between amino 
acid dosing and urinary assay response, it is referred to as a 
phase 3 response. An inverse relationship is referred to as a 
phase 1 response. The phase 3 therapeutic range for urinary 
serotonin is defined as 80–240 µg of serotonin per g of 
c  reatinine. The phase 3 therapeutic range for urinary dop-
amine is defined as 475–1100 µg of dopamine per g of 
creatinine.2–7
Processing, management, and assay of the urine samples 
collected for this study were as follows. Urine samples were 
collected about six hours prior to bedtime, with 4 pm being 
the most frequent collection time point. The samples were 
stabilized in 6 N HCl to preserve the dopamine and serotonin. 
The urine samples were collected after a minimum of one 
week during which time the patient was taking a specific 
daily dosing of amino acid precursors of serotonin and dop-
amine where no doses were missed. Samples were shipped 
to DBS Laboratories (Duluth, MN) which is operated under 
the direction of one of the authors (TU, hospital-based 
pathologist, dual board-certified in laboratory medicine and 
forensic pathology). Urinary dopamine and serotonin were 
assayed utilizing commercially available radioimmunoassay 
kits (3 CAT RIA IB88501 and IB89527, both from Immuno 
Biological Laboratories Inc, Minneapolis, MN). The DBS 
laboratory is accredited as a high complexity laboratory by 
CLIA to perform these assays. OCT assay interpretation 
was performed by one of the authors (MH, NeuroResearch 
Clinics Inc).
Results
The retrospective chart review of this pilot study covered the 
treatment of 85 children aged 4–18 years diagnosed under 
DSM-IV criteria to have ADHD. The age distribution of the 
study group was 4–8 years (n = 7), 9–12 years (n = 36), and 
13–18 years (n = 22). The mean age of the subjects was 
12.2 years. There were 51 boys and 34 girls evenly distributed 
across the three age ranges.
Of the 85 patients, 62 (72.9%) had previously taken a 
stimulant drug for ADHD, and 23 (27.1%) had no history of 
treatment with an ADHD stimulant drug. There were 
28 patients (30.0%) currently taking an ADHD drug while 
57 (70.0%) were not. The breakdown of drugs taken at 
the start of treatment was as follows: 14 were taking amphet-
amine enantiomers; five were taking methylphenidate; five 
were taking atomoxetine; three were taking other drugs not 
specifically defined; and one was taking a combination of 
amphetamine enantiomers with atomoxetine. Parents sought 
treatment under this novel approach primarily due to concerns 
over lack of drug efficacy and/or drug side effects.
The ADHD-RS inventory was administered at the start 
and end of treatment. Results indicated that group Neuropsychiatric Disease and Treatment 2011:7 submit your manuscript | www.dovepress.com
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scores (2 and 3) on the ADHD-RS scale (behavioral 
  symptoms of ADHD) decreased significantly (P , 0.001) 
from the first to the second testing. ADHD-RS results are 
shown in Table 3.
The decrease in 2 and 3 scores shown in Table 3 occurred 
regardless of the variable being investigated, including age 
and gender. This reduction in symptoms is noteworthy. Prior 
to treatment, the number of significant ADHD behavioral 
indicators that were displayed as “often” or “very often” were 
in the 5–9 range. Only two post-treatment behavioral indicators 
were noted. The only variable that approached significance 
(P , 0.08) was gender. More males experienced a decrease 
in symptoms in the ADHD-RS (3) from 8.9 to 2.3 versus 
females in whom this score decreased from 7.1 to 2.2.
In addition to the statistical analysis parameters that were 
identified on the DSM-IV , the following observations were 
calculated relating to other issues. Some of the more compel-
ling findings are included in the tables.
The results shown in Table 4 revealed that 67% of the 
participants achieved significant improvement with only 
amino acid precursors of serotonin and dopamine. Patients 
who achieved no significant relief of symptoms with only 
amino acid precursors represent a subgroup in whom urine 
samples were collected and OCT assay interpretation was 
utilized. In this subgroup, 30.3% achieved significant relief 
of symptoms following two or three urine assays. The total 
percentage of patients showing significant improvement 
was 77%.
Referring to Table 6, a further 10% of patients who had 
taken stimulant drugs in the past reported complete symptom 
relief. There seems to be some advantage for the effective-
ness of the amino acid supplement treatment when there is 
a history of having taken stimulant drugs in the past.
As noted in Table 7, a potential advantage was identified 
with the administration of amino acid precursors relating to 
taking ADHD drugs.
Urine tests did not typically occur until visit 4, and were 
indicated if the patient did not show significant improvement 
with relief of the majority of major ADHD symptoms after 
one week taking level 3 dosing values of Table 1 or Table 2. 
Those who experienced control of symptoms prior to or at 
visit 4 were excluded from urine testing. Results of the 
patients who had an OCT assay are shown in Table 8.
Therefore, it appears that urine testing with OCT assay 
interpretation was beneficial because urinary serotonin and 
dopamine assay interpretation defined the proper dosing 
values. To establish urinary serotonin and dopamine phases 
firmly requires two assays performed with varied amino acid 
precursor dosing values. The significant relief values of 64% 
prior to testing and 70% after two assays noted in Table 7 and 
Table 8 represent only one amino acid dosing change, with 
the confidence of knowing the serotonin and dopamine 
phases.
Discussion
The data generated in the study were compared with data 
generated in double-blind, placebo-controlled studies. 
Tables 9 and 10 summarize the results of this literature 
search. It would appear that the placebo effect is strong in 
ADHD studies, because 28%–40% of placebo patients 
achieved significant relief of symptoms in the atomoxetine 
studies reviewed (Table 10), and 14%–31% had a placebo 
benefit in the methylphenidate study (Table 9).
To meet the criteria for approval under FDA guidelines, 
a drug has to demonstrate efficacy and safety.32 The amino 
acids and cofactors used in this retrospective study are clas-
sified by the FDA as generally recognized and accepted as 
Table 3 Changes in Attention Deficit Hyperactivity Disorder 
rating scale scores at initiation and end of treatment
Group ADHD-RS changes
Pre-Rx End-Rx t-test P
2s 4.6 1.2 8.42 ,0.001
3s 8.3 2.3 12.26 ,0.001
Abbreviations: Rx, treatment; ADHD-RS, Attention-Deficit-Hyperactivity Disorder 
rating scale.
Table  4  Percentage  of  the  entire  group  (n  =  85)  achieving 
significant relief of symptoms by weeks 3 and 8 (P , 0.05)
Week 3 Week 8
Significant relief 67% 77%
Table  5  Percentage  of  the  entire  group  (n  =  85)  achieving 
complete relief of symptoms by weeks 5 and 8
Week 5 Week 8
complete relief 30% 33%
Table 6 The percentage of patients with and without a history 
of taking a stimulant for treatment of ADHD who experienced 
complete relief of symptoms at weeks 5 and 8
Week 5 Week 8
No stimulant drug in past 22% 28%
stimulant drug in past 32% 35%Neuropsychiatric Disease and Treatment 2011:7 submit your manuscript | www.dovepress.com
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safe (GRAS), in the same category as supplemental vitamins 
and minerals.33 There are no safety concerns with the amino 
acids based on this FDA position. All of the amino acids and 
components used in the study are sold in the US over the 
counter without a prescription.
The drugs prescribed for ADHD have potentially controver-
sial concerns associated with them, including neurotransmitter 
depletion, neurotoxicity, drug side effects, and adverse reactions; 
this amino acid approach in comparison has none of these con-
cerns associated with it. This gives a significant advantage to this 
amino acid approach if studies continue to bear out that it is 
similar or superior to prescription ADHD drugs in its efficacy.
This retrospective study was performed in order to focus 
on the structure needed for a formal prospective study. 
In the course of this study, the following observations and 
considerations came to light. The administration of properly 
balanced amino acid precursors of serotonin and dopamine 
with OCT assay interpretation resulted in improvement that 
appears to be superior to methylphenidate and atomoxetine 
(Tables 9 and 10). This certainly provides encouragement to 
undertake further studies.
Even if the finding was that use of serotonin and dopamine 
amino acid precursors with OCT assay interpretation was 
equal to reported efficacy values found with atomoxetine and 
methylphenidate, it is asserted that this approach would be 
superior because it does not share the adverse reactions, 
potential depletion of neurotransmitters, and neurotoxicity 
concerns reported with the group of drugs prescribed for 
ADHD treatment.
There is variance identified and reported in children who 
were and were not taking drugs during this study. Future 
studies need to be designed to address the impact of amino 
acids on subgroups such as this. A further identified issue in 
this study that needs to be corrected in future studies is the 
timeline of the study. In response to the lack of amino acid 
efficacy at visit 4 (taking level 3 dosing values for one week 
from Tables 1 and 2), OCT assay interpretation was started. 
For children in the study for 10 weeks, three urinary tests 
were obtained. Experience leading up to this study suggested 
that a significant number of patients with ADHD do not 
achieve relief of symptoms until both urinary serotonin and 
dopamine are in the phase 3 therapeutic ranges. Data analysis 
revealed that it typically takes 2–8 urine tests with OCT assay 
interpretation to achieve this goal. Provisions need to be made 
in future studies to move away from rigid time guidelines 
and position the studies as a process independent of time 
where the endpoint is urinary serotonin and dopamine in the 
phase 3 therapeutic ranges or relief of symptoms, whichever 
comes first.
Table 7 effect of taking and not taking a prescription ADHD 
drug on the endpoint of the study
Week 5 Week 8
Significant relief Complete relief
Not taking a drug 64% 28%
Table 8 Approximately 59% of patients in the group achieved 
relief of symptoms with administration of amino acids and no 
testing
Urine test group
Two tests 70%
Three tests 78%
Notes: if no response was observed after treatment with the three amino acid 
dosing levels of Table 1 or Table 2, organic cation transporte assay interpretation 
was initiated leading to an increase in the number of patients in the study who 
experienced significant relief of symptoms.
Table 9 Retrospective study results, significant improvement in patients (Table 4) versus reported results in double-blind, placebo-
controlled studies taking methylphenidate
Pilot study results Methylphenidate studies
AA with OCT assay  
interpretation
Study 126 Study 227 Study 328
n 85 154 97 18
% improved 77% (Table 4) 64% 52% 58%
% placebo  
improved
N/A 27% 31% 14%
% drug  
improvement  
over placebo
N/A 37% 21% 44%
Notes: The “% placebo improved” row represents percentage of subjects taking placebo who experienced significant remission of symptoms to the defined threshold of the 
study or greater. The bottom row is the advantage of the drug over placebo in the study cited.
Abbreviations: AA, amino acid; OcT, organic cation transporter.Neuropsychiatric Disease and Treatment 2011:7 submit your manuscript | www.dovepress.com
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It is also suggested that the scrutiny of this retrospective 
study be expanded to identify more phenotype traits. 
  Incorporation of expanded data fields such as this into further 
studies would facilitate more indepth comparison with other 
studies and statistical evaluation of subgroups.
This analysis does provide some initial evidence of the 
efficacy of amino acids in significantly reducing symptoms 
associated with ADHD. Tables 9 and 10 reveal the efficacy 
of this treatment protocol to be potentially superior to results 
seen with prescription drugs. Future studies are needed to 
investigate the reliability of these observed effects. If these 
results can be replicated in controlled studies, then such 
important issues as cause and effect for the changes in ADHD 
symptoms, potential mediating variables, and long-term uses 
can be further investigated and clarified.
Conclusion
Based on the FDA guidelines, the amino acid precursors of 
serotonin and dopamine, used in this study, are classified as 
GRAS, meaning no significant safety concerns exist about 
their use. The next question to ponder is whether the approach 
is effective. The FDA has not set the bar very high in demon-
strating efficacy of prescription drugs. There are numerous 
examples of drugs being approved that are only 7%–13% more 
effective than placebo.4 Under these conditions, it would appear 
that the findings of this study have the potential to demonstrate 
at least that level of efficacy in a prospective study based on 
Tables 9 and 10.
The purpose of this paper was to document formally the 
results and findings generated during the course of this ret-
rospective pilot study involving 85 children, and define 
parameters that allow focus on a future prospective study. 
It is the goal of this paper to spark interest, research, awareness, 
and scrutiny of these findings, and to raise awareness of 
potential neurotransmitter depletion and neurotoxicity issues 
relating to ADHD drugs.
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